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Abstract
Objective: The aim of this study was to compare inpatient outcomes and costs for children with
respiratory syncytial virus and congenital heart disease before and after the change in management
guidelines for respiratory syncytial virus prophylaxis.
Design: Hospital discharge data from the Vizient (formerly University HealthSystem Consortium)
were queried from October 2012 to June 2014 (Era 1) and July 2014 to April 2016 (Era 2) for
patients aged <24 months with an any International Classification of Disease (ICD)-9 or ICD-10
code for congenital heart disease (745-747.49, Q20.0-Q26.4) and a primary or secondary admit-
ting diagnosis of respiratory syncytial virus infection (079.6, J20.5), acute bronchiolitis due to
respiratory syncytial virus (466.11, J21.0) or respiratory syncytial virus pneumonia (480.1, J12.1).
Setting: This study is a review of a national administrative discharge database.
Patients: Respiratory syncytial virus admissions were identified in 1269 patients aged
<24 months with congenital heart disease, with 644 patients in Era 1 and 625 in Era 2. Patients
0–12 months old represented 83% of admissions.
Interventions: Prior to 2014, children aged 0–24 months with congenital heart disease were
eligible to receive respiratory syncytial virus prophylaxis. Updated guidelines, published in 2014,
restricted the recommendation to administer palivizumab respiratory syncytial virus prophylaxis to
children with congenital heart disease only if they are 12 months old.
Outcome measures: The outcome measures are hospital length of stay, ICU admission rate,
mortality, and direct costs.
Results: There was no change in length of stay, ICU admission rate, in-hospital mortality, or direct
costs for children 13–24 months old with congenital heart disease after the change in guidelines.
There were no deaths in 13–24 month olds, regardless of era.
Conclusions: Our findings provide additional support for the new guideline recommendations to
provide respiratory syncytial virus prophylaxis only for children 12 months old with congenital
heart disease.
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1 | INTRODUCTION
Respiratory syncytial virus (RSV) causes a lower respiratory tract
infection in children leading to a high burden of disease. Morbidity and
mortality are higher among premature infants, those with congenital
heart disease (CHD), trisomy 21 and other diseases and malformations
of the respiratory tract.1,2 Currently, there is no antimicrobial therapy
with efficacy against RSV and treatment is primarily supportive.
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Palivizumab is a monoclonal antibody that can be given as a series of
parenteral injections to provide passive immunity to high-risk children,
thereby decreasing the severity of illness. In 2006, the American
Academy of Pediatrics (AAP) released a clinical practice guideline
recommending palivizumab prophylaxis against RSV for those children
identified as high risk based on available data.3 Updated guidelines,
published in July 2014, have decreased the number of patients with
CHD who are recommended to receive palivizumab prophylaxis.
Previously, children with hemodynamically significant cyanotic or acya-
notic CHD were recommended to receive palivizumab if they were
aged 0–24 months at the start of RSV season. This included children
with congestive heart failure who required medical therapy and those
with pulmonary hypertension. The 2014 guidelines restricted the rec-
ommended use of palivizumab to children with CHD only if they are
12 months of age at the start of RSV season.4
The balance between the cost and benefit of palivizumab prophy-
laxis for children with CHD continues to be an area of debate on both a
national and international level. As data have become available after the
2014 RSV prophylaxis guidelines revision, we are now able to better
understand the effects. The goal of the present study is to describe the
impact of the guideline changes on the outcomes and costs associated
with RSV infection in hospitalized children 24 months old with CHD.
2 | METHODS
Vizient (formerly University HealthSystem Consortium) is an alliance of
115 academic medical centers and 165 affiliated hospitals and their
Clinical Data Base/Resource Manager (CDB/RM) is a large administra-
tive database with discharge data from these institutions.5 After
approval from the Institutional Review Board at the University of Ari-
zona, we performed a retrospective review of de-identified discharge
data from inpatient hospitalizations from the CDB/RM from October
2012 to April 2016. This study period allowed for two full RSV seasons
before the guideline change (Era 1, 2012 and 2013) and two full RSV
seasons after the guideline change (Era 2, 2014 and 2015). Of note,
the International Classification of Disease, 10th edition (ICD-10) went
into effect on October 1, 2015, so codes for ICD-9 and ICD-10 were
used to query the database. Inclusion criteria included age 24 months
at admission with an any ICD-9 or ICD-10 code for CHD (745–747.49,
Q20.0-Q26.4) and a primary or secondary admitting diagnosis of RSV
infection (079.6, J20.5), acute bronchiolitis due to RSV (466.11, J21.0)
or RSV pneumonia (480.1, J12.1). The data obtained in this query were
for hospital admissions, and not individual patients, which makes track-
ing patients over time difficult. This data query only included inpatient
admissions, as one of the primary benefits of RSV prophylaxis is to
reduce RSV-associated hospitalizations.
Comparison variables included total length of stay (LOS), ICU
admission rate, in-hospital mortality rate and direct costs. The data
were compared between Era 1 and Era 2 for all admissions for 0–24
months old. Comparisons between Eras were made for 0–12 and 13–
24 months old to better understand the effect of changing the recom-
mended age for palivizumab use from 24 months to 12 months old.
Data were analyzed using independent t-tests and chi-square or
Fisher’s exact test, as appropriate.
3 | RESULTS
A total of 1269 admissions for patients 24 months old with CHD and
RSV were identified for the entire study period, with 644 in Era 1 and
625 in Era 2. Comparisons between Eras for all admissions are shown in
Table 1. Tables 2 and 3 show the comparisons for the 0–12 and 13–24
month groups, respectively. There were more admissions in the 0–
12 month age group compared to the 13–24 month group (1057 vs 212).
Overall mortality was 1.02%, with all of the mortality in the
0–12 month group and no deaths in the 13–24 month group in either
Era. There was a nearly fourfold increase in hospital mortality for the
0–12 month group between Eras (0.56% vs 1.93%, P 5 .051), which
did not reach statistical significance. There was no change in mortality
for the 13–24 month group. There was no difference in costs between
the groups in either Era ($14 482 vs 8187, P 5 .085 and $17 054 vs
11 109, P 5 0.171), and there was no change in costs between Eras.
4 | DISCUSSION
In this retrospective review of a large, national administrative database
of children 24 months old hospitalized with RSV infection, we found
that there was no change in LOS, ICU admission rate, in-hospital
TABLE 1 Hospital outcomes and direct costs for all admissions for
0–24 month old patients with CHD and RSV, with comparisons
between Eras (October 2012–June 2014 and July 2014–April 2016)
Era 1 (n 5 644) Era 2 (n 5 625) P
LOS (days) 8.75 6 12.00 9.49 6 16.17 .354
ICU admission rate (%) 40.18 47.2 .013
Mortality, n (%) 3 (0.47) 10 (1.6) .053
Direct costs ($) 13 527 6 32 437 16 055 6 39 365 .224
Abbreviations: ICU, intensive care unit; LOS, length of stay.
Data are presented as mean 6 standard deviation or n (%).
Data from the Vizient Clinical Data Base/Resource Manager used by
permission of Vizient. All rights reserved.
TABLE 2 Hospital outcomes and direct costs for all admissions for
0–12 month old patients with CHD and RSV, with comparisons
between Eras (October 2012–June 2014 and July 2014–April 2016)
Era 1 (n 5 540) Era 2 (n 5 517) P
LOS (days) 9.27 6 12.58 10.19 6 17.37 .323
ICU admission rate (%) 41.83 48.95 .022
Mortality, n (%) 3 (0.56) 10 (1.93) .051
Direct costs ($) 14 482 6 34 606 17 054 6 41 657 .285
Abbreviations: ICU, intensive care unit; LOS, length of stay.
Data are presented as mean 6 standard deviation or n (%).
Data from the Vizient Clinical Data Base/Resource Manager used by
permission of Vizient. All rights reserved.
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mortality or direct costs for children 13–24 months old with congenital
heart disease after the change in RSV prophylaxis guidelines in July
2014. Using real-world data acquired after the change in RSV prophy-
laxis guidelines, these findings support the updated guidelines that no
longer recommend RSV prophylaxis for children with CHD after 12
months of age.
Overall, there was little change in the measured outcomes among
the study population, with the exception of an increased ICU admission
rate and a trend towards an increase in hospital mortality from Era 1 to
Era 2 in those aged 0–12 months, which is likely clinically important.
Epidemiologic surveillance data have reported an increase of 12.75% in
the incidence of RSV in between the two study Eras.6 This higher
incidence may reflect a higher virulence of the RSV strains during
Era 2, which could explain the increase in LOS and ICU admission and
mortality rates identified, unrelated to the change in prophylaxis
recommendations.
RSV prophylaxis generates potentially significant financial burdens
on families and the healthcare system. A recent study estimated the
cost of $4500 for three doses of palivizumab,7 and extrapolating to a
potential of six doses for an entire RSV season (November to April)
could yield a cost as high as $9000 per patient, assuming perfect com-
pliance. By not providing prophylaxis to the 108 13–24 month olds
with CHD in Era 2 of our study, there are significant potential cost
savings with no change in clinical outcomes compared to Era 1.
A recent analysis of the CARESS Database in Canada found that
children whose CHD remained hemodynamically significant beyond
12 months likely benefitted from continued RSV prophylaxis with fewer
RSV hospitalizations.8 Our data query included all children with any diag-
nosis of CHD, regardless of severity, so we were unable to assess for
this potential effect. Chang has previously reported minimal change in
hospitalization rates for patients with hemodynamically significant CHD
after the 2003 RSV prophylaxis guidelines9, so we felt that looking at
the entire CHD population would be reasonable for the current study.
There are limitations to the use of administrative databases for
research purposes. Admissions were identified using ICD-9 and ICD-10
codes, which have limited detail for CHD, and may also be miscoded
on entry into the database. However, previous reports have shown
that ICD-9 codes in administrative databases have an 80%–85%
specificity for congenital heart disease diagnoses.10 With the large
numbers in our study, it is unlikely that enough admissions were mis-
coded in the database to have altered our findings. We were unable to
isolate individual patient factors in this query, such as administration of
palivizumab prior to hospital admission, multiple comorbidities in the
same patient or specific medications which may have also increased
hospital LOS, ICU admission rate and direct costs and could potentially
limit the generalizability of our findings. While palivizumab administra-
tion rates were not assessed in our study, publicly available pharmaceu-
tical data indicate a decrease in palivizumab revenue from $1.04
billion11 in 2012 to $662 million12 in 2015. Despite these potential
limitations, using a large administrative database allows us to look at a
much larger population of patients than any one institution can provide
to answer questions such as the implications of guideline changes.
5 | CONCLUSION
Using real-world data after changes in national guidelines for RSV pro-
phylaxis for children 24 months old with CHD, we found no signifi-
cant changes in the morbidity or mortality for hospitalized children
with RSV and CHD between 13 and 24 months old. These findings
support the new guideline recommendations to only provide RSV pro-
phylaxis for children 12 months old with CHD. Longer term studies
will be able to better define the impact on clinical outcomes and health
care resource utilization.
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TABLE 3 Hospital outcomes and direct costs for all admissions for
13–24 month old patients with CHD and RSV, with comparisons
between Eras (October 2012–June 2014 and July 2014–April
2016)
Era 1 (n 5 104) Era 2 (n 5 108) P
LOS (days) 6.03 6 7.89 6.12 6 7.53 .932
ICU admission rate (%) 31.65 38.89 .316
Mortality, n (%) 0 (0) 0 (0) 1.000
Direct costs ($) 8187 6 14 468 11 109 6 24 675 .322
Abbreviations: ICU, intensive care unit; LOS, length of stay.
Data are presented as mean 6 standard deviation or n (%).
Data from the Vizient Clinical Data Base/Resource Manager used by
permission of Vizient. All rights reserved.
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